{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
obeticholic acid
to a specific field?
Status:
Investigational
Source:
NCT00041795: Phase 2 Interventional Completed Peripheral Nervous System Diseases
(2002)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Leteprinim is the synthetic purine. It has both anti-excitotoxic neuroprotective properties and enhances the regenerative response of surviving neurons within the central nervous system. Moreover, the experiments in vitro and in vivo reveal that leteprinim can be administered after an excitotoxic event and still produce neuroprotection. This is clearly crucial for any drug designed to treat stroke or any acute central nervous system injury. Therefore, leteprinim has the pharmacological properties required by a drug intended to treat acute stroke as well as a spinal injury. It may be useful in reducing brain injury; it possesses clinical relevance for the treatment of hypoxic-ischemic encephalopathy in the newborn. Leteprinim has the therapeutic potential for use in clinical trials in the treatment of neuronal deterioration in depression.
Status:
Investigational
Source:
NCT01037556: Phase 1/Phase 2 Interventional Unknown status Acute Myelogenous Leukemia
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
PR-104 is a phosphate ester dinitrobenzamide mustard pre-prodrug that is rapidly hydrolyzed systemically to PR-104A, a bioreductive prodrug. PR-104A is in turn activated via reduction by NADPH:cytochrome P450 oxidoreductase and other one-electron reductases in hypoxic cells, and by aldo-keto reductase 1C3 (AKR1C3) independently of oxygen, to the corresponding hydroxylamine (PR-104H) and amine (PR-104M) metabolites. Subsequently, these reactive nitrogen mustards crosslink DNA and cause cytotoxicity in cells. PR-104 is known to have preclinical anti-tumor activity in human tumor xenograft models as mono-therapy and in combination with radiotherapy and chemotherapy. Thrombocytopenia, and to a lesser extent neutropenia, was the dose-limiting toxicity of weekly PR-104. Combination of PR-104 with docetaxel or gemcitabine caused dose-limiting and severe myelotoxicity in patients with advanced solid tumors. PR-104 had been in phase II clinical trial for the treatment of acute myeloid leukemia.
Class (Stereo):
CHEMICAL (ACHIRAL)
Clobuzarit (Clozic) is a compound originally developed for the treatment of atherosclerosis. It was later found to possess antirheumatic and weak anti-inflammatory properties and was evaluated as a disease-modifying antirheumatic drug. Adverse side effects observed in clinical trials have forced the withdrawal of clobuzarit from further consideration.
Status:
Investigational
Source:
NCT02466685: Phase 2 Interventional Completed Bipolar Disorder
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
JNJ-18038683 is a 5-hydroxytryptamine type 7 receptor antagonist with potential antidepressant efficacy. It is under development for the treatment of the bipolar disorder.
Class (Stereo):
CHEMICAL (RACEMIC)
Cliprofen is a non-steroidal anti-inflammatory drug.
Status:
Investigational
Source:
NCT01071928: Phase 2 Interventional Withdrawn Urothelial Carcinoma
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Vadimezan (5,6-dimethyl(xanthenone-4-acetic acid), ASA404, DMXAA) is a fused tricyclic analogue of flavone acetic acid with potential antineoplastic activity. In pre-clinical mouse tumour models it was demonstrated that administration of Vadimezan rapidly leads to disruption of the existing vasculature in the tumour and consequent haemorrhagic necrosis of the tumour. This was consistent with the finding that a single dose of Vadimezan induced a prolonged reduction in the growth of xenografted tumours in animal models. The ability to disrupt the vasculature in these pre-clinical models has been attributed to a rapid induction of cytokines, particularly TNFα (tumour necrosis factor α), serotonin and nitric oxide, resulting in hemorrhagic necrosis and a decrease in angiogenesis. Despite the fact that the molecular targets for the drug remained unknown, the promising pre-clinical results led to Vadimezan being selected for clinical development. Results of Phase I trials showed some restriction of tumour blood flow within 24 h of treatment, although this was not as dramatic as seen in pre-clinical models. Unlike the animal models, there was also very little evidence for the rapid death of blood vessels or for increases in TNFα levels in human tumors. No difference in antitumour activity, cytokine induction or toxicity was observed between two parallel Phase I trials, one dosed weekly and the other dosed every 3 weeks. Therefore the drug proceeded to Phase II clinical trials, dosed every 21 days in combination with chemotherapeutic agents. These trials indicated the drug had small benefits in the treatment of non-small-cell lung cancer and prostate cancer. However, a subsequent Phase III clinical trial was not able to reproduce this response and clinical development was halted.
Class (Stereo):
CHEMICAL (UNKNOWN)
Lucimycin (lucensomycin or etruscomycin) is a polyene antibiotic with antimycotic activity. Originally it was isolated from Streptomyces lucensis n. sp.
Status:
Investigational
Source:
NCT00000650: Not Applicable Interventional Completed HIV Infections
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Ditiocarb, the sodium salt of diethyldithiocarbamate, is a drug with strong antioxidant capacity and chelating activities. It improves the depressed immune responses of newborn and aged mice and mice that are treated with chemotherapy or irradiation. Ditiocarb prevents cisplatin nephrotoxicity in animals without reducing the drug's antitumor activity. Ditiocarb has therapeutic activity in the LP-BM5 murine retrovirus-induced immunodeficiency disease. In that AIDS model, it reduces lymphadenopathy and hypergammaglobulinemia, restores immunocompetence, and prolongs survival. Ditiocarb was safe and reduced the incidence of opportunistic infections in patients with symptomatic HIV infection but ditiocarb had no positive effect on HIV patients. The administration of ditiocarb did not induce any major adverse clinical or biological reactions. Sixty-four patients with nonmetastatic high-risk breast cancer were randomized in a double-blind trial of adjuvant immunotherapy with sodium ditiocarb (DDC) versus placebo. At 6 years, overall survival was 81% in DDC group versus 55%.
Class (Stereo):
CHEMICAL (ACHIRAL)
Class (Stereo):
CHEMICAL (RACEMIC)
Quincarbate is a quinoline derivative patented by N. V. Philips' Gloeilampenfabrieken as diuretic. At 12.5 mg/kg orally in rats Quincarbate increased urine excretion by 130%.
